In a patient with transthyretin amyloid cardiomyopathy, should Camzyos (tafamidis) be continued on the day of surgery, and what anesthetic precautions are recommended?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Camzyos and Anesthesia

Continue Camzyos (mavacamten) on the day of surgery with extreme caution, but strongly consider holding it perioperatively in patients with obstructive hypertrophic cardiomyopathy (HCM) undergoing noncardiac surgery, as factors that aggravate dynamic left ventricular outflow tract (LVOT) obstruction—including anesthesia-induced hemodynamic changes—are harmful and must be avoided.

Critical Clarification: Camzyos vs. Tafamidis

Important: The question appears to conflate two different medications. Camzyos (mavacamten) is FDA-approved for obstructive HCM, while tafamidis (Vyndaqel/Vyndamax) is approved for transthyretin amyloid cardiomyopathy (ATTR-CM). These are distinct diseases requiring different perioperative approaches. The expanded question mentions ATTR-CM but asks about Camzyos—I will address both scenarios.


For Camzyos (Mavacamten) in Obstructive HCM Patients

Perioperative Management Algorithm

Pre-operative Assessment:

  • LVEF must be ≥50% before proceeding with elective surgery 1
  • If LVEF <50%, interrupt Camzyos immediately and postpone elective surgery 1
  • Obtain echocardiogram within 4 weeks of planned surgery to assess LVEF and Valsalva LVOT gradient

Day of Surgery Decision:

  • Consider holding Camzyos 3-5 days before surgery given:
    • The drug's negative inotropic effects that reduce LVEF 1
    • Risk of heart failure from systolic dysfunction 1
    • Potential drug interactions with anesthetic agents
    • The medication takes weeks to reach steady-state, so brief interruption is reasonable 1

Anesthetic Precautions for HCM Patients (On or Off Camzyos)

The 2026 AHA/ACC perioperative guideline provides explicit recommendations for HCM 2:

Avoid these factors that worsen LVOT obstruction:

  • Positive inotropic agents (dobutamine, epinephrine, dopamine)
  • Tachycardia (maintain heart rate control)
  • Reduced preload (hypovolemia, excessive diuresis)
  • Reduced afterload (hypotension)

Recommended intraoperative management:

  • Continue beta-blockers and/or non-dihydropyridine calcium channel blockers throughout the perioperative period 2
  • Maintain adequate preload with intravenous fluids
  • If hypotension develops:
    • Prioritize IV fluid administration first
    • Use alpha-agonists (phenylephrine or vasopressin) rather than beta-agonists 2
    • Consider intravenous beta-blockade to reduce contractility and relieve LVOT obstruction
  • Consider intraoperative transesophageal echocardiography (TEE) to evaluate LVOT obstruction if hemodynamic instability occurs 2
  • Maintain sinus rhythm due to LV hypertrophy and decreased compliance 2

Post-operative Monitoring

  • Obtain echocardiogram before restarting Camzyos to confirm LVEF ≥50% 1
  • Monitor for heart failure symptoms or worsening clinical status 1
  • If intercurrent illness (infection, arrhythmia) occurs, delay Camzyos restart 1

For Tafamidis in ATTR-CM Patients

Perioperative Management

Continue tafamidis through the perioperative period as:

  • It is a transthyretin stabilizer that prevents amyloid fibril formation 3
  • Well-tolerated with safety profile similar to placebo 4, 5, 6
  • Reduces all-cause mortality and cardiovascular hospitalizations 3, 4
  • No specific perioperative contraindications exist in guidelines
  • Abrupt discontinuation may accelerate disease progression

Anesthetic Considerations for ATTR-CM

ATTR-CM patients have restrictive cardiomyopathy with:

  • Reduced ventricular compliance
  • Diastolic dysfunction
  • Conduction abnormalities
  • Autonomic dysfunction

Key perioperative principles:

  • Maintain preload (these patients are preload-dependent)
  • Avoid excessive fluid administration (risk of pulmonary edema)
  • Maintain sinus rhythm (atrial contribution to ventricular filling is critical)
  • Avoid tachycardia (impairs diastolic filling)
  • Monitor for arrhythmias (high risk of atrial fibrillation, conduction disease)
  • Consider invasive hemodynamic monitoring for major surgery

Common Pitfalls to Avoid

  1. Confusing Camzyos with tafamidis—completely different drugs for different diseases
  2. Using inotropes in HCM patients—worsens LVOT obstruction 2
  3. Allowing hypovolemia in HCM—exacerbates obstruction 2
  4. Stopping tafamidis unnecessarily—no evidence supports perioperative discontinuation
  5. Failing to check LVEF before surgery in Camzyos patients—mandatory per FDA label 1
  6. Ignoring drug interactions—Camzyos has significant CYP2C19/CYP3A4 interactions 1

Summary Algorithm

If patient has obstructive HCM on Camzyos:

  • Check LVEF <4 weeks before surgery
  • If LVEF ≥50%: Consider holding Camzyos 3-5 days pre-op
  • Continue beta-blockers/calcium channel blockers
  • Avoid inotropes, maintain preload, use alpha-agonists for hypotension
  • Check LVEF before restarting Camzyos post-op

If patient has ATTR-CM on tafamidis:

  • Continue tafamidis perioperatively
  • Manage restrictive physiology: maintain preload, avoid fluid overload
  • Monitor for arrhythmias
  • Maintain sinus rhythm and avoid tachycardia

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.